| Published Date | Report Code | No. of Pages | Report Format |
| August – 2020 | AMR-9030 | 110 | PDF / Excel |
Cell and gene therapy can possibly wipe out and forestall a few chronic issues as well as life-threatening diseases, heart problems, AIDS, cystic fibrosis, and age-related issues among others. The treatment furnishes complete cure to patients affected with chronic issues instead of the simplicity of side effects offered by different treatments. The gene therapy idea was developed in 1989. From that point forward, scientists have been endeavoring to use the capability of gene therapy for the treatment of uncommon and hereditary illnesses just as sicknesses for which complete cure isn’t available yet.
The expanding utilization of cell therapy products for treating burns, venous leg ulcers, diabetic foot ulcers, wounds, and weight ulcers in hospitalized patients is another factor adding to market growth of cell & gene therapy market. As indicated by the American College of Surgeons, around 1–2% of the worldwide populace encounters chronic injuries in the course of their life.
Moreover, this analytical repository offers fully-fledged market analysis with respect to different economical aspects of the global market. This global market intelligence report offers a detailed elaboration on the regional and competitive landscape of the global market. The report is presented with industrial insights and aims to provide a strong strategic plan for the sustainable development of the global market over the upcoming years. Collectively, this informative investigation research report presents the development of the present market along with the historical developments and future projections.
The global cell & gene therapy market size was esteemed at USD 6.2 billion in 2019 and is anticipated to expand at a CAGR of 25% during the forecast period 2019-2028. The increased commonness of many serious diseases is adding to the development of the cell and gene therapy market. Roughly one out of three grown-ups experience more than one chronic condition or various incessant conditions across the globe. Chronic diseases predominantly include CVDs, lung problems, cancer, and diabetes among others. A combination of factors including rising number of patients with different diseases, product launches and approvals favorable regulatory support and special designations for cell and gene therapy products, and growing demand for car t-cell therapy products are the major factors enabling the growth of the global cell & gene therapy market. However, the high cost of cell & gene therapy products and manufacturing difficulties are factors expected to hinder the market growth
The global cell & gene therapy market is anticipated to grow significantly on the back of a high number of population affected by chronic diseases, and increasing number cancer & diabetes cases worldwide. The rising government initiatives and drug approvals for the prevention of cell & gene therapy are further bolstering the growth of the global cell & gene therapy market. The market for cell & gene therapy is projected to cross US$ 9 billion by 2028.
Technological advancements in cell and gene therapy is one of the key factors anticipated to fuel the worldwide cell and gene therapy market during the years to come. Developing advancements in cell and gene therapy, for example, restrictive cell lines, gene vectors, cell expansion and division system, and single-use bioprocessing reactors, have become essential methods by which single items have been changed into a strong product portfolio. For instance, Immunicum has offered three stages for example gene editing, CAR-T cell development, and T-cell primers. These innovations allows the organization to propel its series of immuno-oncology patients. Immunicum has two advances for example IMM-2 stage and IMM-3 stage experiencing preclinical examinations for use in the treatment of various sorts of cancers.
Based on product type perspective in cell & gene therapy industry, cell & gene therapy can be classified into cell therapy and gene therapy. In 2019, cell therapy was the most dominant segment contributing a share of more than 70% of the overall market. The launch of innovative and breakthrough products and the high adoption of CAR T-cell based therapies are the factors responsible for the growth of the cell therapy segment.
On the flip side, the gene therapy segment is anticipated to register the fastest growth during the forecast period. Gene therapy products are expected to replace many cell therapy products in the years to come and to account for a market share of more than 50%, which is just double of that in 2018.
North America dominated the global cell & gene therapy market accounting for a market share of more than 40% of market revenue. This can be attributed to high prevalence of genetic disorders and the increasing number of product launches. For instance, According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries is around 135 million in U.S. In fact, North America has more than 400 companies that are actively engaged in research and product development of cell and gene therapy products.
Asia Pacific region is anticipated to emerge as a major market during the years to come. This can be associated with rising prevalence of chronic diseases in the region. China is renowned as the global focus point for new cell and gene therapy development. In the current scenario, the number of ongoing gene therapy clinical trials in China has exceeded the number of trials in the U.S.
Noticeable players within the market are
The players of cell & gene therapy industry are focusing majorly on developing and launching more advanced products with more features to gain a competitive edge in the market. Strategies such as partnerships, new product development, licensing agreements, and other legally binding agreements are being reported by major players to become the market leader. For instance, In October 2018, Gilead planned to increase the number of gene therapy centers to 90. As of June 2018, around 68 treatment centers were operating in the U.S
This report bifurcates cell & gene therapy revenue opportunities at worldwide, territorial, and national levels and gives an investigation of the most recent industry patterns in each of the sub-segments during the estimated period. For the reason of this ponder, Alchemy Market Research has sectioned the worldwide cell & gene therapy market report on the premise of product type strategy, application strategy, end-user strategy, and regional analysis:
This report answers key questions such as
Chapter 1. Executive Summary
Chapter 2. Market Introduction
Chapter 3. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints
Chapter 4. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
Chapter 5. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Product Type
5.1. Cell Therapy
5.2. Gene Therapy
Chapter 6. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Application
6.1. Oncology
6.2. Dermatology
6.3. Musculoskeletal
6.4. Others
Chapter 7. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By End-user
7.1. Hospitals
7.2. Wound Care Centers
7.3. Cancer Care Centers
7.4. ASCs
7.5. Others
Chapter 8. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Region
8.1. North America
8.2. Europe
8.3. Asia-Pacific
8.4. Latin America
8.5. Middle East & Africa
Chapter 9. North America Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
9.1. North America Cell & Gene Therapy Market– By Product Type
9.1.1. Cell Therapy
9.1.2. Gene Therapy
9.2. North America Cell & Gene Therapy Market– By Application
9.2.1. Oncology
9.2.2. Dermatology
9.2.3. Musculoskeletal
9.2.4. Others
9.3. North America Cell & Gene Therapy Market– By End-user
9.3.1. Hospitals
9.3.2. Wound Care Centers
9.3.3. Cancer Care Centers
9.3.4. ASCs
9.3.5. Others
9.4. North America Cell & Gene Therapy Market– By Country
9.4.1. U.S.
9.4.2. Canada
Chapter 10. Europe Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
10.1. Europe Cell & Gene Therapy Market– By Product Type
10.1.1. Cell Therapy
10.1.2. Gene Therapy
10.2. Europe Cell & Gene Therapy Market– By Application
10.2.1. Oncology
10.2.2. Dermatology
10.2.3. Musculoskeletal
10.2.4. Others
10.3. Europe Cell & Gene Therapy Market– By End-user
10.3.1. Hospitals
10.3.2. Wound Care Centers
10.3.3. Cancer Care Centers
10.3.4. ASCs
10.3.5. Others
10.4. Europe Cell & Gene Therapy Market– By Country
10.4.1. Germany
10.4.2. France
10.4.3. UK
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
Chapter 11. Asia Pacific Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
11.1. Asia Pacific Cell & Gene Therapy Market– By Product Type
11.1.1. Cell Therapy
11.1.2. Gene Therapy
11.2. Asia Pacific Cell & Gene Therapy Market– By Application
11.2.1. Oncology
11.2.2. Dermatology
11.2.3. Musculoskeletal
11.2.4. Others
11.3. Asia Pacific Cell & Gene Therapy Market– By End-user
11.3.1. Hospitals
11.3.2. Wound Care Centers
11.3.3. Cancer Care Centers
11.3.4. ASCs
11.3.5. Others
11.4. Asia-Pacific Cell & Gene Therapy Market– By Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. South Korea
11.4.5. Rest of Asia-Pacific
Chapter 12. Latin America Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
12.1. Latin America Cell & Gene Therapy Market– By Product Type
12.1.1. Cell Therapy
12.1.2. Gene Therapy
12.2. Latin America Cell & Gene Therapy Market– By Application
12.2.1. Oncology
12.2.2. Dermatology
12.2.3. Musculoskeletal
12.2.4. Others
12.3. Latin America Cell & Gene Therapy Market– By End-user
12.3.1. Hospitals
12.3.2. Wound Care Centers
12.3.3. Cancer Care Centers
12.3.4. ASCs
12.3.5. Others
12.4. Latin America Cell & Gene Therapy Market– By Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
Chapter 13. Middle East & Africa Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
13.1. Middle East & Africa Cell & Gene Therapy Market– By Product Type
13.1.1. Cell Therapy
13.1.2. Gene Therapy
13.2. Middle East & Africa Cell & Gene Therapy Market– By Application
13.2.1. Oncology
13.2.2. Dermatology
13.2.3. Musculoskeletal
13.2.4. Others
13.3. Middle East & Africa Cell & Gene Therapy Market– By End-user
13.3.1. Hospitals
13.3.2. Wound Care Centers
13.3.3. Cancer Care Centers
13.3.4. ASCs
13.3.5. Others
13.4. Middle East & Africa Cell & Gene Therapy Market– By Country
13.4.1. UAE
13.4.2. Saudi Arabia
13.4.3. Turkey
13.4.4. Rest of Middle East & Africa
Chapter 14. Competitive Analysis
14.1.1. Competition Dashboard
14.1.2. Company Profiles
14.1.2.1. Biogen
14.1.2.2. Gilead Sciences, Inc.
14.1.2.3. Amgen, Inc.
14.1.2.4. Novartis AG
14.1.2.5. Orchard Therapeutics Plc
14.1.2.6. Spark Therapeutics, Inc. (A Part of Hoffmann-La Roche)
14.1.2.7. Molmed S.P.A.
14.1.2.8. Anges, Inc.
14.1.2.9. Bluebird Bio, Inc.
14.1.2.10. Human Stem Cells Institute (HSCI)
14.1.2.11. SIBIONO Genetech Co., Ltd.
14.1.2.12. Shanghai Sunway Biotech Co., Ltd
14.1.2.13. Uniqure N.V.
14.1.2.14. Gensight Biologics S.A.
14.1.2.15. Celgene Corporation
Cell and gene therapy can possibly wipe out and forestall a few chronic issues as well as life-threatening diseases, heart problems, AIDS, cystic fibrosis, and age-related issues among others. The treatment furnishes complete cure to patients affected with chronic issues instead of the simplicity of side effects offered by different treatments. The gene therapy idea was developed in 1989. From that point forward, scientists have been endeavoring to use the capability of gene therapy for the treatment of uncommon and hereditary illnesses just as sicknesses for which complete cure isn’t available yet.
The expanding utilization of cell therapy products for treating burns, venous leg ulcers, diabetic foot ulcers, wounds, and weight ulcers in hospitalized patients is another factor adding to market growth of cell & gene therapy market. As indicated by the American College of Surgeons, around 1–2% of the worldwide populace encounters chronic injuries in the course of their life.
Moreover, this analytical repository offers fully-fledged market analysis with respect to different economical aspects of the global market. This global market intelligence report offers a detailed elaboration on the regional and competitive landscape of the global market. The report is presented with industrial insights and aims to provide a strong strategic plan for the sustainable development of the global market over the upcoming years. Collectively, this informative investigation research report presents the development of the present market along with the historical developments and future projections.
The global cell & gene therapy market size was esteemed at USD 6.2 billion in 2019 and is anticipated to expand at a CAGR of 25% during the forecast period 2019-2028. The increased commonness of many serious diseases is adding to the development of the cell and gene therapy market. Roughly one out of three grown-ups experience more than one chronic condition or various incessant conditions across the globe. Chronic diseases predominantly include CVDs, lung problems, cancer, and diabetes among others. A combination of factors including rising number of patients with different diseases, product launches and approvals favorable regulatory support and special designations for cell and gene therapy products, and growing demand for car t-cell therapy products are the major factors enabling the growth of the global cell & gene therapy market. However, the high cost of cell & gene therapy products and manufacturing difficulties are factors expected to hinder the market growth
The global cell & gene therapy market is anticipated to grow significantly on the back of a high number of population affected by chronic diseases, and increasing number cancer & diabetes cases worldwide. The rising government initiatives and drug approvals for the prevention of cell & gene therapy are further bolstering the growth of the global cell & gene therapy market. The market for cell & gene therapy is projected to cross US$ 9 billion by 2028.
Technological advancements in cell and gene therapy is one of the key factors anticipated to fuel the worldwide cell and gene therapy market during the years to come. Developing advancements in cell and gene therapy, for example, restrictive cell lines, gene vectors, cell expansion and division system, and single-use bioprocessing reactors, have become essential methods by which single items have been changed into a strong product portfolio. For instance, Immunicum has offered three stages for example gene editing, CAR-T cell development, and T-cell primers. These innovations allows the organization to propel its series of immuno-oncology patients. Immunicum has two advances for example IMM-2 stage and IMM-3 stage experiencing preclinical examinations for use in the treatment of various sorts of cancers.
Based on product type perspective in cell & gene therapy industry, cell & gene therapy can be classified into cell therapy and gene therapy. In 2019, cell therapy was the most dominant segment contributing a share of more than 70% of the overall market. The launch of innovative and breakthrough products and the high adoption of CAR T-cell based therapies are the factors responsible for the growth of the cell therapy segment.
On the flip side, the gene therapy segment is anticipated to register the fastest growth during the forecast period. Gene therapy products are expected to replace many cell therapy products in the years to come and to account for a market share of more than 50%, which is just double of that in 2018.
North America dominated the global cell & gene therapy market accounting for a market share of more than 40% of market revenue. This can be attributed to high prevalence of genetic disorders and the increasing number of product launches. For instance, According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries is around 135 million in U.S. In fact, North America has more than 400 companies that are actively engaged in research and product development of cell and gene therapy products.
Asia Pacific region is anticipated to emerge as a major market during the years to come. This can be associated with rising prevalence of chronic diseases in the region. China is renowned as the global focus point for new cell and gene therapy development. In the current scenario, the number of ongoing gene therapy clinical trials in China has exceeded the number of trials in the U.S.
Noticeable players within the market are
The players of cell & gene therapy industry are focusing majorly on developing and launching more advanced products with more features to gain a competitive edge in the market. Strategies such as partnerships, new product development, licensing agreements, and other legally binding agreements are being reported by major players to become the market leader. For instance, In October 2018, Gilead planned to increase the number of gene therapy centers to 90. As of June 2018, around 68 treatment centers were operating in the U.S
This report bifurcates cell & gene therapy revenue opportunities at worldwide, territorial, and national levels and gives an investigation of the most recent industry patterns in each of the sub-segments during the estimated period. For the reason of this ponder, Alchemy Market Research has sectioned the worldwide cell & gene therapy market report on the premise of product type strategy, application strategy, end-user strategy, and regional analysis:
This report answers key questions such as
Chapter 1. Executive Summary
Chapter 2. Market Introduction
Chapter 3. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints
Chapter 4. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
Chapter 5. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Product Type
5.1. Cell Therapy
5.2. Gene Therapy
Chapter 6. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Application
6.1. Oncology
6.2. Dermatology
6.3. Musculoskeletal
6.4. Others
Chapter 7. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By End-user
7.1. Hospitals
7.2. Wound Care Centers
7.3. Cancer Care Centers
7.4. ASCs
7.5. Others
Chapter 8. Global Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Region
8.1. North America
8.2. Europe
8.3. Asia-Pacific
8.4. Latin America
8.5. Middle East & Africa
Chapter 9. North America Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
9.1. North America Cell & Gene Therapy Market– By Product Type
9.1.1. Cell Therapy
9.1.2. Gene Therapy
9.2. North America Cell & Gene Therapy Market– By Application
9.2.1. Oncology
9.2.2. Dermatology
9.2.3. Musculoskeletal
9.2.4. Others
9.3. North America Cell & Gene Therapy Market– By End-user
9.3.1. Hospitals
9.3.2. Wound Care Centers
9.3.3. Cancer Care Centers
9.3.4. ASCs
9.3.5. Others
9.4. North America Cell & Gene Therapy Market– By Country
9.4.1. U.S.
9.4.2. Canada
Chapter 10. Europe Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
10.1. Europe Cell & Gene Therapy Market– By Product Type
10.1.1. Cell Therapy
10.1.2. Gene Therapy
10.2. Europe Cell & Gene Therapy Market– By Application
10.2.1. Oncology
10.2.2. Dermatology
10.2.3. Musculoskeletal
10.2.4. Others
10.3. Europe Cell & Gene Therapy Market– By End-user
10.3.1. Hospitals
10.3.2. Wound Care Centers
10.3.3. Cancer Care Centers
10.3.4. ASCs
10.3.5. Others
10.4. Europe Cell & Gene Therapy Market– By Country
10.4.1. Germany
10.4.2. France
10.4.3. UK
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
Chapter 11. Asia Pacific Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
11.1. Asia Pacific Cell & Gene Therapy Market– By Product Type
11.1.1. Cell Therapy
11.1.2. Gene Therapy
11.2. Asia Pacific Cell & Gene Therapy Market– By Application
11.2.1. Oncology
11.2.2. Dermatology
11.2.3. Musculoskeletal
11.2.4. Others
11.3. Asia Pacific Cell & Gene Therapy Market– By End-user
11.3.1. Hospitals
11.3.2. Wound Care Centers
11.3.3. Cancer Care Centers
11.3.4. ASCs
11.3.5. Others
11.4. Asia-Pacific Cell & Gene Therapy Market– By Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. South Korea
11.4.5. Rest of Asia-Pacific
Chapter 12. Latin America Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
12.1. Latin America Cell & Gene Therapy Market– By Product Type
12.1.1. Cell Therapy
12.1.2. Gene Therapy
12.2. Latin America Cell & Gene Therapy Market– By Application
12.2.1. Oncology
12.2.2. Dermatology
12.2.3. Musculoskeletal
12.2.4. Others
12.3. Latin America Cell & Gene Therapy Market– By End-user
12.3.1. Hospitals
12.3.2. Wound Care Centers
12.3.3. Cancer Care Centers
12.3.4. ASCs
12.3.5. Others
12.4. Latin America Cell & Gene Therapy Market– By Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
Chapter 13. Middle East & Africa Cell & Gene Therapy Market– Analysis and Revenue Forecast 2019-2028
13.1. Middle East & Africa Cell & Gene Therapy Market– By Product Type
13.1.1. Cell Therapy
13.1.2. Gene Therapy
13.2. Middle East & Africa Cell & Gene Therapy Market– By Application
13.2.1. Oncology
13.2.2. Dermatology
13.2.3. Musculoskeletal
13.2.4. Others
13.3. Middle East & Africa Cell & Gene Therapy Market– By End-user
13.3.1. Hospitals
13.3.2. Wound Care Centers
13.3.3. Cancer Care Centers
13.3.4. ASCs
13.3.5. Others
13.4. Middle East & Africa Cell & Gene Therapy Market– By Country
13.4.1. UAE
13.4.2. Saudi Arabia
13.4.3. Turkey
13.4.4. Rest of Middle East & Africa
Chapter 14. Competitive Analysis
14.1.1. Competition Dashboard
14.1.2. Company Profiles
14.1.2.1. Biogen
14.1.2.2. Gilead Sciences, Inc.
14.1.2.3. Amgen, Inc.
14.1.2.4. Novartis AG
14.1.2.5. Orchard Therapeutics Plc
14.1.2.6. Spark Therapeutics, Inc. (A Part of Hoffmann-La Roche)
14.1.2.7. Molmed S.P.A.
14.1.2.8. Anges, Inc.
14.1.2.9. Bluebird Bio, Inc.
14.1.2.10. Human Stem Cells Institute (HSCI)
14.1.2.11. SIBIONO Genetech Co., Ltd.
14.1.2.12. Shanghai Sunway Biotech Co., Ltd
14.1.2.13. Uniqure N.V.
14.1.2.14. Gensight Biologics S.A.
14.1.2.15. Celgene Corporation
